FATE Therapeutics Inc (FATE)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.02
- As of
Kresmion compiles this page from FATE's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
FATE THERAPEUTICS INC (FATE): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-05.
See the full FATE dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for FATE on one page. Preview it with sample data, then open it live with a free account.
Preview the FATE dossierActive events for FATE
- mediumEarnings above estimates
Q3-2026: Beat consensus by 9.3%, EPS $-0.25 vs $-0.2755 estimate
- high13F: funds added
3 tracked funds increased FATE this 2026Q2, institutional consensus
- high13F: large reduction
CITADEL ADVISORS LLC cut 69% of FATE (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +171% to FATE (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +2892% to FATE (2026Q2)
FREE, NO ACCOUNT
Every event on FATE, as it fires
You are seeing 5 of 10 events recorded on FATE since 2026-07-24.
The five above landed across 3 days. The other 5 were recorded on 2 other days. 7 of the 10 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
FATE positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 31189P102 · 2026Q3 | $5.6M | 0.01% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, FATE
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
More data on FATE
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in FATE on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on FATE in the last 180 days.
Upstream: SEC EDGAR filings for FATE
Kresmion, "FATE THERAPEUTICS INC (FATE) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/FATE. Upstream data: SEC EDGAR filings for FATE.
Link to this data (HTML):
<a href="https://kresmion.com/research/FATE">FATE THERAPEUTICS INC (FATE) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow FATE on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to FATE for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.